Viable tumour-derived epithelial cells (circulating tumour cells or CTCs) have been
identified in peripheral blood from cancer patients and are probably the origin of intractable …

Background Bone metastases are a major burden in men with advanced prostate cancer.
We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

Background Darolutamide is a structurally unique androgen-receptor antagonist that is
under development for the treatment of prostate cancer. We evaluated the efficacy of …

Background Androgen-deprivation therapy is well-established for treating prostate cancer
but is associated with bone loss and an increased risk of fracture. We investigated the effects …

Background Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall
survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We …

Background Bone metastases are a major cause of morbidity and mortality in men with
prostate cancer. Preclinical studies suggest that osteoclast inhibition might prevent bone …

Background Darolutamide is a potent androgen-receptor inhibitor that has been associated
with increased overall survival among patients with nonmetastatic, castration-resistant …

Background Treatment with a gonadotropin-releasing hormone agonist decreases bone
mineral density and increases the risk of fracture in men with prostate cancer. We conducted a …

Background Apalutamide, a competitive inhibitor of the androgen receptor, is under development
for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men …